Abeona Therapeutics’ (ABEO) Buy Rating Reiterated at FBR & Co
Abeona Therapeutics Inc (NASDAQ:ABEO)‘s stock had its “buy” rating reaffirmed by investment analysts at FBR & Co in a research report issued on Friday.
Other equities analysts have also recently issued research reports about the stock. Maxim Group reiterated a “buy” rating and set a $14.00 price target on shares of Abeona Therapeutics in a research report on Friday, March 10th. Cantor Fitzgerald reiterated a “buy” rating and set a $21.00 price target on shares of Abeona Therapeutics in a research report on Friday, May 12th. Jefferies Group LLC reiterated a “buy” rating and set a $11.00 price target on shares of Abeona Therapeutics in a research report on Wednesday, April 26th. HC Wainwright set a $20.00 price objective on shares of Abeona Therapeutics and gave the stock a “buy” rating in a report on Monday, February 6th. Finally, Rodman & Renshaw restated a “buy” rating and issued a $20.00 price objective (up previously from $17.00) on shares of Abeona Therapeutics in a report on Tuesday, February 7th. One research analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $15.18.
Abeona Therapeutics (NASDAQ:ABEO) opened at 5.55 on Friday. Abeona Therapeutics has a 52-week low of $2.31 and a 52-week high of $9.44. The stock’s 50 day moving average is $5.55 and its 200-day moving average is $5.44. The company’s market cap is $223.42 million.
Abeona Therapeutics (NASDAQ:ABEO) last announced its quarterly earnings results on Thursday, May 18th. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.02. Abeona Therapeutics had a negative net margin of 2,029.60% and a negative return on equity of 26.65%. The company had revenue of $0.19 million for the quarter, compared to analysts’ expectations of $0.28 million. Equities research analysts predict that Abeona Therapeutics will post ($0.59) EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Abeona Therapeutics’ (ABEO) Buy Rating Reiterated at FBR & Co” was originally posted by American Banking News and is the property of of American Banking News. If you are reading this article on another website, it was stolen and republished in violation of U.S. and international copyright & trademark law. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/05/27/abeona-therapeutics-abeo-buy-rating-reiterated-at-fbr-co.html.
A number of large investors have recently made changes to their positions in ABEO. A.R.T. Advisors LLC acquired a new stake in shares of Abeona Therapeutics during the fourth quarter worth $117,000. Allianz Asset Management AG acquired a new stake in shares of Abeona Therapeutics during the fourth quarter worth $236,000. Kavi Asset Management LP boosted its stake in shares of Abeona Therapeutics by 477.6% in the fourth quarter. Kavi Asset Management LP now owns 365,600 shares of the biopharmaceutical company’s stock worth $1,773,000 after buying an additional 302,300 shares during the period. RTW Investments LLC acquired a new stake in shares of Abeona Therapeutics during the third quarter worth $116,000. Finally, Knoll Capital Management LP acquired a new stake in shares of Abeona Therapeutics during the third quarter worth $8,036,000. Institutional investors and hedge funds own 17.79% of the company’s stock.
About Abeona Therapeutics
Abeona Therapeutics, Inc (Abeona), formerly PlasmaTech Biopharmaceuticals, Inc, is focused on developing and delivering gene therapy and plasma-based products for rare diseases. The Company’s lead programs are ABO-101 (AA9 NAGLU) and ABO-102 (scAAV9 SGHG), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (Mucopolysaccharidosis (MPS) IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians.
Receive News & Ratings for Abeona Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.